Pfizer moves to a not-for-profit model for drug sales in 45 low-income countries – Endpoints News

Leading the way in increasing access to cheaper medicines around the world, Pfizer said Wednesday that it will provide all current and future patent-protected medicines and vaccines available in the US or EU on a non-profit basis to around 1.2 billion people in 45 income countries.

Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to sign this agreement, which will also seek to open new paths for fast and efficient procurement and regulatory processes to reduce the usual delays in the availability of new medicines and vaccines in these countries. .

“Combined with additional investments to strengthen Africa’s public health systems and pharmaceutical regulators, the Agreement is an important step towards sustainable health security for countries of all income levels,” said Rwandan President Paul Kagame. it’s a statement.

Pfizer says that so far it has committed to providing 23 medicines and vaccines that treat various infectious diseases, cancers, and rare and inflammatory diseases, which together could save about a million lives each year in these countries, as well as help at least 500,000 more people fighting chronic diseases. diseases that significantly impact quality of life.

The Bill and Melinda Gates Foundation is also helping, funding Pfizer’s work on new vaccine candidates for Group B prevention. Streptococcus, which is one of the leading causes of stillbirth and neonatal mortality in low-income countries. The two sides are also discussing opportunities to support the development of the RSV vaccine, another maternal vaccine.

Pfizer’s experimental RSV vaccine candidate builds on discoveries made at NIH, which detailed the crystal structure of prefusion F, a key form of the viral fusion protein that RSV uses to attack human cells. In March, Pfizer’s vaccine candidate received a Breakthrough Designation from the FDA for the prevention of RSV-associated lower respiratory tract illness in infants from birth to six months of age through active immunization of pregnant women.

Pfizer CEO Albert Bourla told the financial times in an interview at the World Economic Forum in Davos, Switzerland, that this deal is unrelated to Pfizer’s opposition to a proposal in the WTO to provide patent flexibilities around Covid-19 vaccines.

“I don’t connect the two at all. Frankly, I think it’s the right thing to do,” Bourla said.

Meanwhile, on the Covid-19 front, he said he is worried about complacency around the world and warned that the consequences could be seen in three to six months.

Add Comment